Business
Enveric Biosciences Appoints Carter Ward as Chief Financial Officer
NAPLES, Fla., April 12, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing
About this update from Enveric Biosciences, Inc.
[{"type":"text","content":"NAPLES, Fla., April 12, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) (\"Enveric\" or the \"Company\"), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it has appointed Carter Ward as Chief Financial Officer, effective May 15th, 2021. Mr. Ward is replacing John Van Buiten, who is expected to remain in a consulting role with the company, supporting Mr. Ward both during the transition and moving forward.\n\"Mr. Ward will be joining our team with extensive public company leadership experience in life sciences, SEC reporting and the capital markets,\" said David Johnson, Chairman and CEO of Enveric. \"Having a hands-on financial leader who has managed companies in various stages, from startup to expansion and turnaround, I have no doubt that Mr. Ward will help to continue driving the growth and success at Enveric. Our team sincerely thanks Mr. Van Buiten for his dedication to the Company, especially his commitment in working tirelessly with management through our recent go-public transaction. We are excited that he will remain with Enveric as a consultant.\"\nPrior to joining Enveric, Mr. Ward, who has over 30 years of industry experience after starting his career at KPMG, most recently served as CFO at Elite Pharmaceuticals, a specialty pharmaceutical company that develops and manufactures oral, controlled-release products using proprietary technology for manufacturing generic pharmaceuticals. During his tenure there, Mr. Ward successfully negotiated and executed capital raises, developed strategic initiatives, created financial models and led financial reporting efforts. \nBefore joining Elite, Mr. Ward also worked on the finance and supply chain team at Actavis USA, the U.S. subsidiary of European-based Actavis Group. At Actavis, Mr. Ward spearheaded the successful reengineering of the company's outbound supply chain, achieving a $3.5 million annual cost reduction and 75 percent improvement in order-to-delivery time. Additionally, Mr. Ward worked at Centennial Communications, and internationally at Ceejay Healthcare in India and Petro Pharma in Singapore.\n\"Since becoming a public company in late-December 2020, Enveric has already achieved notable strategic milestones, working diligently to execute its vision of bringing n...